INTEGRATED SAFETY OF LESINURAD, A NOVEL URIC ACID REABSORPTION INHIBITOR FOR THE TREATMENT OF GOUT

被引：0

作者：

Becker, M. A. ^{[1
]}

Keenan, R. T. ^{[2
]}

Khanna, P. P. ^{[3
]}

Malamet, R. ^{[4
]}

Bos, K. ^{[4
]}

Li, J. ^{[4
]}

Hu, J. ^{[5
]}

White, W. B. ^{[6
]}

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

[2] Duke Univ, Sch Med, Durham, NC USA

[3] Univ Michigan, Ann Arbor, MI 48109 USA

[4] AstraZeneca, Wilmington, DE USA

[5] Formerly Ardea Biosci Inc, San Diego, CA USA

[6] Univ Connecticut, Sch Med, Farmington, CT USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷

关键词：

D O I：

10.1136/annrheumdis-2017-eular.3674

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

THU0444

引用

页码：375 / 376

页数：2

共 50 条

[41] Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout Patients
Kim, Jinseok
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2175 - 2176
[42] The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
Okui, Daisuke
Sasaki, Tomomitsu
Fushimi, Masahiko
Ohashi, Tetsuo
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (SUPPL 1) : 92 - 102
[43] The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
Daisuke Okui
Tomomitsu Sasaki
Masahiko Fushimi
Tetsuo Ohashi
Clinical and Experimental Nephrology, 2020, 24 : 92 - 102
[44] Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
Nicola Dalbeth
Graeme Jones
Robert Terkeltaub
Dinesh Khanna
Maple Fung
Scott Baumgartner
Fernando Perez-Ruiz
Arthritis Research & Therapy, 21
[45] USE OF XANTHINE OXIDASE INHIBITOR ALLOPURINOL IN CONTROL OF HYPERURICAEMIA GOUT AND URIC ACID CALCULI
EMMERSON, BT
AUSTRALASIAN ANNALS OF MEDICINE, 1967, 16 (03): : 205 - &
[46] Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials
Takahashi, Toshinari
Beppu, Takanobu
Hidaka, Yuji
Hosoya, Tatsuo
CLINICAL AND EXPERIMENTAL HYPERTENSION, 2021, 43 (08) : 730 - 741
[47] Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease
Ashcroft, John A.
BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
[48] The Treatment Of Gout In Relation To The 2012 Uric Acid Target Guidelines In The US Population
Juraschek, Stephen
Kovell, Lara
Miller, Edgar, III
Gelber, Allan C.
ARTHRITIS AND RHEUMATISM, 2013, 65 : S500 - S501
[49] GOUT AND URIC-ACID NEPHROPATHY - SOME NEW ASPECTS IN DIAGNOSIS AND TREATMENT
LOFFLER, W
SIMMONDS, HA
GROBNER, W
KLINISCHE WOCHENSCHRIFT, 1983, 61 (24): : 1233 - 1239
[50] Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects
Gillen, Michael
Shen, Zangong
Miner, Jeffrey N.
ARTHRITIS & RHEUMATOLOGY, 2016, 68

← 1 2 3 4 5 →